Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies.

41 Global trials 41 Global trials
3500 Patients enrolled 3500 Patients enrolled

Boston Scientific Drug Eluting Clinical Program

Discover and download Boston Scientifics Drug Eluting Clinical Programm now.


Favorable twelve-month data for RANGER

Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.


RANGER DCB : Clinically proven in both randomized and real-world clinical trials RANGER DCB : Clinically proven in both randomized and real-world clinical trials

RANGER DCB: Clinically proven in both randomized and real-world clinical trials!

The RANGER™ SFA trial exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.



MAJESTIC clinical study MAJESTIC clinical study

MAJESTIC clinical study : Unprecedented Results at 2 years!

The Eluvia Drug-Eluting Stent System demonstrated an unprecedented 92.5% Freedom from TLR at 2 years.